Business Wire

Autodoc GmbH adapts its storage capacity to strong company growth

Share

Autodoc, the benchmark in online retail for car spare parts in Europe, is expanding its logistics locations in Szczecin and Berlin. With above-average growth in recent years, the demands placed on logistics have become increasingly extensive. In 2018 as a whole, around five million orders were processed and delivered at the two Autodoc warehouses in Berlin and Szczecin. In the current year, the 6 million mark in orders was already exceeded by mid-November. In order to meet Europe-wide demand in the future as well, Autodoc has rented additional warehouse space in Szczecin and at its main location in Berlin.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191206005110/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The Autodoc warehouse in Szczecin, Poland, will provide around 27,000 m² of storage space from spring 2020. (Photo: Business Wire)

Expansion of logistics capacities is a key growth factor

Autodoc saw itself as a European company from the outset and identified early on the potential for scaling up that was available to online retailers at European level. Today Autodoc is active in 26 European countries. The provision of additional logistics capacity is an essential factor for further expansion across Europe. Last year, the existing premises were pushed to their limits in order to meet the growing demand across Europe. Autodoc has therefore decided to expand its storage capacities in Berlin and Szczecin to ensure Autodoc’s continued growth.

Autodoc managing director, Alexej Erdle comments:“With the expansion of the warehouse space at the two logistics locations of Berlin and Szczecin, we have created the basis for the sustained strong growth of the company. We expect sales of over EUR 600 million by 2019.”

With an additional 3,700 m2, the logistics location in Szczecin recently grew to a total of 13,700 m². In Berlin, 4,600 m² were added. The existing storage area at the company’s headquarters in Berlin Lichtenberg has thus grown from around 16,800 m2 to over 21,000 m². In Poland, additional space is needed mostly for stockpiling imported goods.

At the same time Autodoc carried out further logistics optimization measures in the current year. A country division of the two warehouse locations ensures shorter parcel delivery times and does away with unnecessary journeys. This also helps to save CO2 emissions and makes good economic sense.

New Autodoc warehouse in Poland from spring 2020

Autodoc will be able to put an additional warehouse into operation at its existing site in Szczecin from spring 2020. The new warehouse with an area of around 13,000 m² will increase the total storage area in Szczecin to around 26,700 m² and support the company’s continued strong growth.

For Alexej Erdle, there is no doubt about it: “We want to continue to grow – also in turnover. Through our constant optimizations we protect the environment, save money and prepare our structures for further growth. We are already active in many countries and are constantly gaining new customers”.

About AUTODOC

AUTODOC is Europe’s leading online retailer for car spare parts. As the fastest-growing company in this sector, with sales growth of 63% in the financial year 2018 to around EUR 415 million (2017: EUR 254 million), AUTODOC is aiming to further expand its position. Thanks to its successful expansion, AUTODOC is now represented in 25 other European countries in addition to Germany. AUTODOC pursues a strong customer focus on social media, through technical support in the respective national language and a demand-oriented product range currently comprising almost 2.5 million items from 545 brand manufacturers for 128 car brands. From brake systems, car body parts, shock absorbers and springs, exhaust systems, interior elements, steering systems and clutches to air conditioning systems, heating systems, repair kits and engine oil, the online retailer offers a wide range of products. In June 2018, the company celebrated its tenth anniversary. AUTODOC GmbH is based in the Berlin district of Lichtenberg and is fully owner-managed.

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Thomas Casper
Head of Press and Public Relations & Communication
Kurfürstendamm 22
10719 Berlin
Tel.: +49 30 2084 78 237
E-mail: t.casper@autodoc.eu
www.autodoc.de

cometis AG
Matthias Kunz
Tel.: +49 611 20 585 5-64
kunz@cometis.de
www.cometis.de

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 15:00:00 EEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

IonQ Unanimously Appoints Peter Chapman as Next Chairman of the Board of Directors26.4.2024 14:30:00 EEST | Press release

IonQ (NYSE: IONQ), a leader in the quantum computing industry, announced today the appointment of Peter Chapman as its next Chairman of the Board and Harry You as the Lead Independent Director of the Board, effective at the close of IonQ’s upcoming Annual General Meeting on June 5, 2024. Both appointments were disclosed in a proxy statement issued on April 25, 2024. Peter Chapman has also been nominated for re-election as a Class III director at the meeting, and his chairmanship will take effect assuming he is re-elected. “Last quarter we were delighted to have appointed Robert Cardillo and Bill Scannell to our Board of Directors. In addition, the Board unanimously appointed Peter Chapman to serve as its next Chairman following the annual meeting given his half-decade worth of contributions to IonQ and his strong progress transitioning IonQ from an academic to a commercial company,” said Niccolo de Masi, Chairman of the Nominating & Corporate Governance Committee of IonQ’s Board. “Unde

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye